EMA accepts Biomarin application for label extension of dwarfism drug
The European Medicines Agency starts review of Biomarin’s application seeking an indication extension of achondroplasia drug Voxzogo for children younger than two years.
by ulrich quistgaard, translated by daniel pedersen
The European Medicines Agency (EMA) has accepted an application from Biomarin seeking to extend the indication of achondroplasia drug Voxzogo to include children under two years old.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin axes 4% of global workforce
For subscribers
FDA sets deadline for Ascendis Pharma drug decision
For subscribers
